Literature DB >> 28009493

Daratumumab and Blood-Compatibility Testing.

Meletios A Dimopoulos, Pieter Sonneveld, Huabin Sun.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 28009493     DOI： 10.1056/NEJMc1613868

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  2 in total

1.  Daratumumab (anti-CD38) induces loss of CD38 on red blood cells.

Authors:  Harold C Sullivan; Christian Gerner-Smidt; Ajay K Nooka; Connie M Arthur; Louisa Thompson; Amanda Mener; Seema R Patel; Marianne Yee; Ross M Fasano; Cassandra D Josephson; Richard M Kaufman; John D Roback; Sagar Lonial; Sean R Stowell
Journal:  Blood       Date:  2017-04-03       Impact factor: 25.476

2.  Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

Authors:  Ajai Chari; Attaya Suvannasankha; Joseph W Fay; Bertrand Arnulf; Jonathan L Kaufman; Jainulabdeen J Ifthikharuddin; Brendan M Weiss; Amrita Krishnan; Suzanne Lentzsch; Raymond Comenzo; Jianping Wang; Kerri Nottage; Christopher Chiu; Nushmia Z Khokhar; Tahamtan Ahmadi; Sagar Lonial
Journal:  Blood       Date:  2017-06-21       Impact factor: 22.113
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.